CCNU (Lomustine): Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 March 2024

24 March 2024

  • curprev 06:0906:09, 24 March 2024‎ Lazy talk contribs‎ 528 bytes +528‎ Created page with "{{TreatmentInfo |drug_name=CCNU (Lomustine) |FDA_approval=Yes |used_for=Glioblastoma |clinical_trial_phase=Phase 3 (Germany) |common_side_effects=Hematological toxicity, nausea, vomiting, and pulmonary toxicity |OS_with=23 months median survival, with 47% at 2 years |usefulness_rating=4 |notes=A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outco..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=CCNU_(Lomustine)"